Evaluation of Tools to Predict Risk of Cardiovascular Event or Death Post-Transplant

Austin, Texas—Due primarily to comorbid conditions, patients who are recipients of renal transplantation are at increased risk for development of cardiovascular disease. Currently, there are no cardiovascular risk stratification tools that are effective and non-invasive for this patient population. Kimberly L. Hoffman, MSN, ACNP-BC, of the University of Cincinnati College of Medicine, assessed the utility of two tools, the Framingham Risk Score and the Revised Cardiac Risk Index, to predict cardiovascular events at 1- and 3-year time points for renal transplant recipients.

Results of the retrospective single-center analysis were reported during a poster session at the NKF 2018 Spring Clinical Meetings. The poster was titled Cardiovascular Risk Stratification Tool Evaluation in Renal Transplant Recipients.

The analysis included data on 231 patients who received living or deceased donor renal allografts between 2001 and 2011. Patients were men and women 30 to 70 years of age. The Framingham tool was applied to baseline data findings. The cardiac index was calculated for two scores—pretransplant serum creatinine and immediate post-transplant serum creatinine. To assess for a cardiovascular event and/or death, the evaluation was conducted for each participant at 1 and 3 years following transplantation.

The Framingham tool did not show a significant ability to predict cardiovascular events or death at either time point. The cardiac risk index using the pretransplant serum creatinine level was also not predictive of cardiovascular event or death at 1 year post-transplant. At 3 years post-transplant, the cardiac risk index was not significantly predictive of death, but did show significance (P<.05) for prediction of cardiovascular events.

Source: Hoffman KL. Cardiovascular risk stratification tool: evaluation in renal transplant recipients. Abstract of a poster presented at the National Kidney Foundation 2018 Spring Clinical Meetings, April 10-14, 2018, Austin, Texas.